HAO1 and primary hyperoxaluria type 1: In 2017, an RNAi targeting the HAO1 mRNA demonstrated efficient downregulation of GO protein levels, which resulted in a dose-dependent reduction of oxalate accumulation, a non-pathological increase of glycolate excretion, and therapeutic efficacy across multiple preclinical models of PH1 (Liebow et al, 2017).